Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

EPT Disclosure

16 Apr 2010 10:32

RNS Number : 3074K
Credit Suisse Securities (Eur) Ltd
16 April 2010
 

FORM 38.5 (a)

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS

WITH RECOGNISED INTERMEDIARY STATUS

DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(a) of the Takeover Code)

1. KEY INFORMATION

Name of exempt principal trader

Credit Suisse Securities (Europe) Limited

Company dealt in

Ark Therapeutics Group PLC

Class of relevant security to which the dealings being disclosed relate (Note 1)

Ordinary Shares

Date of dealing

15-Apr-2010

2. DEALINGS (Note 2)

(a) Purchases and sales

Total number of securities purchased

Highest price paid (Note 3)

Lowest price paid (Note 3)

120002

0.105 (GBP)

0.1 (GBP)

 

Total number of securities sold

Highest price received (Note 3)

Lowest price received (Note 3)

120002

0.103 (GBP)

0.1 (GBP)

(b) Derivatives transactions (other than options)

Product name, e.g. CFD

Long/short (Note 4)

Number of securities (Note 5)

Price per unit (Note 3)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Product name,e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 5)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 3)

(ii) Exercising

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 3)

3. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Date of disclosure

16-Apr-2010

Contact name

Collins,Carolyn/ Crawley, Simon

Telephone number

0207 8880241

Name of offeree/offeror with which connected

Ark Therapeutics Group PLC

Nature of connection (Note 6)

ADVISOR

Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
EMMSFUSUMFSSEEL
Date   Source Headline
1st Mar 201310:50 amRNSForm 8.3 - [Ark Therapeutics]
26th Feb 20135:35 pmRNSHolding(s) in Company
26th Feb 20139:33 amRNSForm 8.3 - Ark Therapeutics Group PLC
25th Feb 201311:55 amRNSForm 8.3 - Ark Therapeutics Group PLC
25th Feb 201311:27 amRNSHolding(s) in Company
22nd Feb 20132:41 pmRNSHolding(s) in Company
21st Feb 20131:24 pmPRNForm 8.3 - Ark Therapeutics plc
21st Feb 201310:56 amRNSHolding(s) in Company
20th Feb 201312:54 pmPRNForm 8.3 - Ark Therapeutics plc
20th Feb 201312:11 pmRNSForm 8.3 - [Ark Therapeutics Group PLC]
19th Feb 20134:40 pmRNSSecond Price Monitoring Extn
19th Feb 20134:35 pmRNSPrice Monitoring Extension
15th Feb 201312:57 pmRNSForm 8.3 - Ark Therapeutics Group PLC
15th Feb 201310:39 amPRNForm 8.3 - Ark Therapeutics Group plc
12th Feb 201312:25 pmRNSHolding(s) in Company
7th Feb 20133:05 pmRNSHolding(s) in Company
7th Feb 20131:41 pmPRNForm 8.3 - Ark Therapeutics Group
6th Feb 20134:43 pmRNSForm 8.3 - Ark Therapeutics
6th Feb 201311:18 amPRNForm 8.3 - Ark Therapeutics Group
6th Feb 201311:02 amRNSForm 8 (OPD)
5th Feb 20134:35 pmRNSPrice Monitoring Extension
5th Feb 20132:48 pmRNSForm 8.3 - Ark Therapeutics Group PLC
4th Feb 20132:43 pmRNSForm 8.3 - Ark Therapeutics Group Plc
4th Feb 20131:10 pmRNSForm 8.3 - Ark Therapeutics
4th Feb 201310:11 amRNSForm 8.3 - [Ark Therapeutics]
1st Feb 20133:10 pmRNSForm 8.3 - Ark Therapeutics Group PLC
1st Feb 20132:53 pmRNSForm 8.3 - Ark Therapeutics Amendment
1st Feb 201312:41 pmRNSForm 8.3 - Ark Therapeutics Group plc
31st Jan 20133:42 pmRNSForm 8.3 - Ark Therapeutics Group PLC
31st Jan 20131:40 pmRNSForm 8.3 - Ark Therapeutics Group Plc
31st Jan 20131:31 pmRNSForm 8.3 - Ark Therapeutics Group plc
31st Jan 201312:02 pmRNSForm 8.3 - ARK Therapeutics plc
31st Jan 201311:51 amBUSForm 8.3 - Ark Therapeutics Group Plc
31st Jan 201311:14 amPRNForm 8.3 - Ark Therapeutics Group
30th Jan 20134:03 pmRNSForm 8.3 - Ark Therapeutics Group Plc
30th Jan 20137:00 amRNSStrategic Review Update
24th Jan 20133:33 pmRNSHolding(s) in Company
21st Jan 20137:00 amRNSCompany Update
4th Dec 20123:40 pmRNSBlocklisting Six Monthly Return
30th Nov 20127:00 amRNSFrench Tax Credit for Research and Development
8th Nov 20127:00 amRNSInterim Management Statement
15th Oct 20127:00 amRNSRe Agreement
26th Sep 20127:00 amRNSManufacturing Agreement Update
29th Aug 20127:00 amRNSHalf Yearly Report
24th Aug 20124:40 pmRNSSecond Price Monitoring Extn
24th Aug 20124:35 pmRNSPrice Monitoring Extension
14th Aug 20127:00 amRNSRe Agreement
25th Jul 20127:00 amRNSManufacturing Partnership
5th Jul 20127:00 amRNSDirectorate Change
11th Jun 20127:00 amRNSAppointment of New Head of Business Development

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.